Lipid Regulators Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Lipid Regulators Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The lipid regulators market is expected to register a CAGR of 5.1% over the forecast period.

The pandemic witnessed higher demand for lipid-based supplements owing to their health-beneficial properties. For instance, as per the study published in October 2021, titled "COVID-19 and lipids. The role of lipid disorders and statin use in the prognosis of patients with SARS-CoV-2 infection", it has been shown that COVID-19 infection influences the lipid profile, leading to dyslipidemia, which might require appropriate treatment. Owing to its antiviral, anti-inflammatory, immunomodulatory, and cardioprotective activities, statin therapy has been considered a valuable tool to improve COVID-19 outcomes. Thus, due to the growing spread of COVID-19, patients' consumption of lipid nutritional products has increased, enabling faster recovery from COVID-19 infection, thereby having a positive impact on the market growth.

Lipids are vital biomolecules in the proper functioning of the metabolism. For example, cholesterol acts as a precursor for steroid hormones and bile acids. However, any kind of lipid in excess is considered toxic. Lipid regulators, apart from cholesterol control, deal with fragile bones with high susceptibility to breaking, which is termed osteoporosis, and also keep a check on myocardial infarctions, which is commonly known as a heart attack. Recently, due to the increase in the prevalence of diseases like dyslipidemia, there has been an increasing demand for lipid regulators. Dyslipidemia increases the chance of clogged arteries (atherosclerosis) and heart attacks, strokes, or other circulatory concerns, especially in smokers. Moreover, the geriatric population is more prone to cardiovascular diseases. In the elderly age group, lipid-altering medication has been proven to reduce cardiovascular risk.

According to the 2022 American Heart Association (AHA) report, approximately 244.1 million people were living with ischemic heart disease (IHD) around the world, and North Africa and the Middle East, Central and South Asia, and Eastern Europe had the highest prevalence rates of IHD in the world in 2020. This burden of cardiovascular diseases is further expected to increase due to the high prevalence of associated risk factors such as hypertension, obesity, smoking, diabetes, and others, along with a sedentary lifestyle. Thus, the use of lipid regulators is expected to increase, which will drive growth in the lipid regulators market over the forecast period.

Moreover, with the increase in the elderly age group, the lipid regulators market is expected to surge as this age group is prone to various chronic diseases such as cardiovascular diseases. As per the World Aging Report 2022, the share of the global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. By 2050, the number of people aged 65 years or over worldwide is projected to be more than twice the number of children under age 5 and about the same as the number of children under age 12. Therefore, with the increasing aging population, the demand for lipid regulators is expected to increase, which is further expected to boost the growth of the market over the forecast period.

Hence, these factors are aiding the growth of the market over the analysis period. However, a lack of awareness regarding lipid regulators and the presence of low-cost generics has been hampering the market growth.

Key Market TrendsBranded Statins Segment is Expected to Witness Growth Over the Forecast Period

Branded statins are more effective than other lipid-regulating drugs at lowering LDL-cholesterol concentrations. Some of the statins available in the market include atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin. Hence, the demand for these statins is expected to increase as the prevalence of dyslipidemia increases. Dyslipidemia, defined as elevated total or low-density lipoprotein (LDL) cholesterol levels, or low levels of high-density lipoprotein (HDL) cholesterol, is an important risk factor for coronary heart disease (CHD) and stroke.

The diabetic population is also more prone to a higher incidence of dyslipidemia. The statins competitively inhibit HMG-CoA reductase and lower lipid levels in diseased populations. As per the World Health Organization, there are over 400 million people with diabetes across the world, and its treatment constitutes around 12% of the total healthcare expenditure on a global scale. It has emerged as a global epidemic and affected millions worldwide. Currently, about 10% of all diabetes cases are type 1 and the remaining are type 2. Hence, the increasing prevalence of diabetes may result in an increased prevalence of dyslipidemia, which is expected to boost the growth of the segment over the forecast period.

Thus, owing to the abovementioned factors, the market segment is anticipated to witness growth over the forecast period.

North America is Expected to Dominate the Lipid Regulators Market

According to OECD data published in May 2021, the North American countries of the United States and Mexico have one of the highest prevalence of obesity and diabetes in the world. Moreover, being overweight or obese increases the chances of developing the common type of diabetes, type 2 diabetes. As the presence of diabetes increases the risk of dyslipidemia, the demand for lipid regulators is expected to increase over the coming years.

As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) data updated in December 2020, an estimated 34.2 million people have diabetes (or 10.5% of the United States population). As per the same source, an estimated 26.9 million people of all ages have been diagnosed with diabetes (8.2% of the United States population). Of the people diagnosed with diabetes, 210,000 are children and adolescents younger than age 20, including 187,000 with type 1 diabetes. Thus, the increasing cases of diabetes are expected to increase the demand for lipid regulators in the region, which is expected to boost the growth of the market over the forecast period.

Moreover, according to the Centers for Disease Control and Prevention (CDC) data updated in May 2022, from March 2017 to March 2020, 41.9% of Americans were obese. The prevalence of obesity in the United States increased from 30.5 to 41.9%. The prevalence of severe obesity rose from 4.7% to 9.2% during the same period. The CDC has identified obesity as a leading cause of preventable death in the United States, and it is one of the leading causes of chronic diseases both worldwide and in the United States. Obesity-related disorders, known as comorbidities, include cardiovascular diseases and some cancers. Thus, increasing obesity requires cholesterol control, wherein lipid regulators come into play, which is expected to boost the growth of the market over the forecast period.

Thus, due to the aforementioned factors, the lipid regulators market in the North American region is expected to grow over the analysis period.

Competitive Landscape

The lipid regulators market is highly competitive and fragmented as the majority of the lipid regulators are manufactured by the global key players. Market leaders with more funds for research and better distribution systems have established their position in the market. Some market players are AstraZeneca, AbbVie Inc., Amgen, Pfizer, and Teva Pharmaceuticals.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.